New CMO to Drive Clinical Development at Neuroprotection Biotech

Spanish biotech company Bionure, specialised in neuroprotection, has appointed Dr. Lucia Septien as chief medical officer, as the company is preparing for a phase 2 clinical study with its lead compound, BN201. Her wealth of experience in drug development and regulatory challenges will help the company finalise and deploy its clinical development plan and regulatory strategy and execute the upcoming phase 2 program.

Dr Septien has worked as a clinical doctor in neurology and psychiatry and held senior medical and regulatory roles with a focus on neuroscience at major pharmaceutical companies, including Pfizer, Wyeth, GSK, Servier and Ipsen. She later moved to the biotech sector as chief medical officer at DBV Technologies.

"We warmly welcome Lucia to Bionure. With her sensitivity for patients, her solid experience in CNS drug development and her leadership skills, she will strengthen our team," said Laurent Nguyen, CEO of Bionure. “We are convinced of her ability to successfully implement our neuroprotection projects.”

 “In my practice as a medical doctor and drug developer, I encountered many patients made desperate by the progression of their neurodegenerative disease,” said Lucia Septien. “I am thrilled to join an enthusiastic team dedicated to changing the course of the current path towards disability.”

 Barcelona-based Bionure recently completed its successful phase 1 study investigating the safety, tolerability and pharmacokinetics of BN201, a first-in-class compound that demonstrated neuroprotective activity and stimulation for remyelination. The company’s prime focus areas are Acute Optic Neuritis (AON) and Multiple Sclerosis (MS), for which there are still high unmet medical needs.